**Background of BCL3 Antibody**
BCL3 (B-cell lymphoma 3) is a proto-oncogene-encoded protein belonging to the IκB family, which regulates NF-κB signaling—a critical pathway in immune responses, inflammation, and cell survival. BCL3 functions as a transcriptional co-regulator, binding to NF-κB homodimers (e.g., p50/p52) to modulate their nuclear retention and activity. Unlike classical IκB proteins that sequester NF-κB in the cytoplasm, BCL3 stabilizes NF-κB complexes in the nucleus, either enhancing or repressing target gene expression depending on cellular context.
Dysregulation of BCL3 is implicated in cancers, particularly B-cell malignancies, as well as inflammatory diseases. Overexpression of BCL3 has been observed in chronic lymphocytic leukemia, breast cancer, and colorectal carcinomas, often correlating with poor prognosis. Its role in promoting cell proliferation, inhibiting apoptosis, and sustaining chronic inflammation makes it a therapeutic target.
BCL3 antibodies are essential tools for studying its expression, localization, and interactions. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Validated antibodies help identify BCL3’s involvement in disease mechanisms or drug responses. Researchers must select antibodies specific to BCL3 isoforms or post-translationally modified forms, depending on experimental goals. Commercial BCL3 antibodies are typically raised against epitopes in the N-terminal or ankyrin repeat domains, with cross-reactivity validated across species (human, mouse, rat). Proper controls are crucial to ensure specificity, given BCL3’s homology with other IκB proteins.